For research use only. Not for therapeutic Use.
Masitinib mesylate（Cat No.:I000269）is a selective tyrosine kinase inhibitor that targets key receptors, including c-Kit, PDGFR, and Lyn, involved in cell proliferation, survival, and immune regulation. It is used primarily in cancer research, particularly in mast cell tumors, gastrointestinal stromal tumors (GIST), and certain types of leukemia. Masitinib’s ability to inhibit kinases involved in tumor growth and immune response makes it valuable not only in oncology but also in inflammatory and neurodegenerative disease research. Its multi-targeted approach offers potential for treating a wide range of disorders, including cancers and chronic diseases.
| Catalog Number | I000269 |
| CAS Number | 1048007-93-7 |
| Synonyms | N-(4-methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide methanesulfonate |
| Molecular Formula | C29H34N6O4S2 |
| Purity | ≥95% |
| Target | PDGFR |
| Solubility | 10 mM in DMSO |
| Storage | Store at -20°C |
| IC50 | 200 nM (Kit); 540 nM/800 nM(PDGFRα/β) [1] |
| IUPAC Name | methanesulfonic acid;4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-yl-1,3-thiazol-2-yl)amino]phenyl]benzamide |
| InChI | InChI=1S/C28H30N6OS.CH4O3S/c1-20-5-10-24(16-25(20)31-28-32-26(19-36-28)23-4-3-11-29-17-23)30-27(35)22-8-6-21(7-9-22)18-34-14-12-33(2)13-15-34;1-5(2,3)4/h3-11,16-17,19H,12-15,18H2,1-2H3,(H,30,35)(H,31,32);1H3,(H,2,3,4) |
| InChIKey | TXCWBWKVIZGWEQ-UHFFFAOYSA-N |
| SMILES | CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC(=CS4)C5=CN=CC=C5.CS(=O)(=O)O |
| Reference | <p style=/line-height:25px/> <br>[2]. Lawrence J, et al. Masitinib demonstrates anti-proliferative and pro-apoptotic activity in primary and metastatic feline injection-site sarcoma cells. Vet Comp Oncol, 2011, doi: 10.1111/j.1476-5829.2011.00291.x. <br>[3]. Hahn KA, et al. Masitinib is safe and effective for the treatment of canine mast cell tumors. J Vet Intern Med, 2008, 22(6), 1301-1309. </p> |
